These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24905093)

  • 21. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses.
    Jimbo Sotomayor R; Toscano CM; Sánchez Choez X; Vilema Ortíz M; Rivas Condo J; Ghisays G; Haneuse S; Weinberger DM; McGee G; de Oliveira LH
    Vaccine; 2020 Oct; 38(45):7033-7039. PubMed ID: 32981782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012.
    Griffin MR; Mitchel E; Moore MR; Whitney CG; Grijalva CG;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(44):995-8. PubMed ID: 25375070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    de Melo Araujo AC; da Silva Aragão J; de Souza WV; Rodrigues LC; de Barros Miranda-Filho D
    Vaccine; 2023 Jul; 41(32):4719-4725. PubMed ID: 37353456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
    Suarez V; Michel F; Toscano CM; Bierrenbach AL; Gonzales M; Alencar AP; Ruiz Matus C; Andrus JK; de Oliveira LH
    Vaccine; 2016 Sep; 34(39):4738-4743. PubMed ID: 27521230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.
    Ouldali N; Varon E; Levy C; Angoulvant F; Georges S; Ploy MC; Kempf M; Cremniter J; Cohen R; Bruhl DL; Danis K
    Lancet Infect Dis; 2021 Jan; 21(1):137-147. PubMed ID: 32702302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation.
    Dagan R; Ben-Shimol S; Greenberg D; Givon-Lavi N
    Clin Infect Dis; 2021 Apr; 72(7):1200-1207. PubMed ID: 32140705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
    Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
    Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia.
    Elemraid MA; Rushton SP; Shirley MD; Thomas MF; Spencer DA; Eastham KM; Hampton F; Gorton R; Pollard K; Gennery AR; Clark JE;
    Epidemiol Infect; 2013 Aug; 141(8):1697-704. PubMed ID: 23084696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study.
    Luca DL; Kwong JC; Chu A; Sander B; O'Reilly R; McGeer AJ; Bloom DE
    Clin Infect Dis; 2018 Feb; 66(4):541-547. PubMed ID: 29029063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of pneumonia in the pre-pneumococcal conjugate vaccine era in children 2-59 months of age, in Ulaanbaatar, Mongolia, 2015-2016.
    von Mollendorf C; La Vincente S; Ulziibayar M; Suuri B; Luvsantseren D; Narangerel D; de Campo J; de Campo M; Nguyen C; Demberelsuren S; Mungun T; Mulholland EK
    PLoS One; 2019; 14(9):e0222423. PubMed ID: 31509593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.